Conference Correspondent

GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.
CALGB 10404, a randomized phase 2 study, compares different fludarabine chemoimmunotherapy regimens in patients with non-del(11q) chronic lymphocytic leukemia (CLL).
This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation.

Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.

The following summaries represent a sample of the many real-world, evidence-based studies presented at the 29th Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), March 27-30, 2017, in Denver, CO.
Washington, DC—With tremendous changes occurring in healthcare and particularly in oncology, discussion about the current trends and demands facing stakeholders in optimizing value in cancer care dominated the Sixth Annual Conference of the Association for Value-Based Cancer Care, held September 27-29, 2016, and co-chaired by Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY; and Burt Zweigenhaft, BS, President, National Association of Specialty Pharmacy; and Editor-in-Chief, Value-Based Cancer Care.

In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.

Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.

In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.

Page 3 of 8
Results 21 - 30 of 80
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME